Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Oresti
Observed names:
Oresti, Sara,
S. Oresti
Institutions:
Vita-Salute San Raffaele University,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
IRCCS Ospedale San Raffaele
Observed institutions:
Vita-Salute San Raffaele University,
University of Milan,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
IRCCS Ospedale San Raffaele
ORCID:
0009-0006-3879-2092
Observed ORCID:
0009-0006-3879-2092
OpenAlex ID:
A5065657755
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022
·
L. Cantini
, G. Mentrasti
, et al.
·
ESMO Open
·
73
PDF
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023
·
Antonio Nuccio
, Giuseppe Viscardi
, et al.
·
European Journal of Cancer
·
49
PDF
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
2024
·
E.G. Pizzutilo
, A.G. Agostara
, et al.
·
ESMO Open
·
22
PDF
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
2023
·
Elio Gregory Pizzutilo
, Rebecca Romanò
, et al.
·
Cancer Research
·
20
PDF
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
2024
·
Fabrizio Citarella
, Kazuki Takada
, et al.
·
Journal of Translational Medicine
·
13
PDF
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
2023
·
Francesco Maria Venanzi
, Marta Bini
, et al.
·
Cancer Treatment Reviews
·
13
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience
2024
·
Francesca Rita Ogliari
, Alberto Traverso
, et al.
·
Lung Cancer
·
7
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
2022
·
E.G. Pizzutilo
, A.G. Agostara
, et al.
·
Journal of Thoracic Oncology
·
6
PDF
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’
2022
·
L. Cantini
, G. Mentrasti
, et al.
·
ESMO Open
·
6
PDF
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
2025
·
Sara Oresti
, Fabio Salomone
, et al.
·
EClinicalMedicine
·
5
PDF
55P EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
2023
·
S.T. Riva
, F.R. Ogliari
, et al.
·
ESMO Open
·
3
PDF
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
2023
·
Alberto Giuseppe Agostara
, Laura Roazzi
, et al.
·
Expert Review of Respiratory Medicine
·
3
996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
2022
·
E.G. Pizzutilo
, G. Cerea
, et al.
·
Annals of Oncology
·
3
118P Role of PD-L1 and pathological complete response (pCR) with neoadjuvant (NEO) or perioperative (PERIOP) immune-checkpoint inhibitors (ICI) and platinum-based chemotherapy (PCT) in resectable non-small cell lung cancer (NSCLC): A systematic review and metanalysis
2024
·
A. Nuccio
, G. Viscardi
, et al.
·
ESMO Open
·
2
OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study
2021
·
L. Cantini
, G. Mentrasti
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing
2026
·
Fabrizio Citarella
, Francesco M Venanzi
, et al.
·
Lung Cancer
·
1
1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
2024
·
A. Nuccio
, F. Salomone
, et al.
·
Annals of Oncology
·
1
PDF
86P Artificial intelligence tools to predict early progression of non-small cell lung cancer patients treated with immunotherapy: Preliminary evidence from a single-centre experience of black-box and white-box models pairing
2024
·
F.R. Ogliari
, A. Traverso
, et al.
·
ESMO Open
·
1
Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis
2026
·
Cosimo Simone Matichecchia
, Fabrizio Fanizzi
, et al.
·
Cancers
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
2026
·
Ludovica Mollica
, Elena Tassi
, et al.
·
Clinical Lung Cancer
AI-HOPE lung cancer: a multicenter real-world registry integrating artificial intelligence for metastatic non-small-cell lung cancer
2026
·
F.R. Ogliari
, M. Ferrara
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study
2026
·
Alessandro Leonetti
, Vanessa Callegari
, et al.
·
Tumori Journal
PDF
369P Family history of cancer (FHC) in non-small cell lung cancer (NSCLC): A cross-sectional-prospective study to guide germline referral
2026
·
F. Citarella
, F.M. Venanzi
, et al.
·
ESMO Open
PDF
562eP Tumor, host and treatment related predictive factors for immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)
2026
·
F.M. Venanzi
, D. Zotti
, et al.
·
ESMO Open
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study
2026
·
Giulia Pasello
, Claudia Proto
, et al.
·
Frontiers in Oncology
PDF
Show more works
View as search
Works count:
44
Citation count:
230
H-index:
7
I10-index:
6
Year
Topic
Type